Stocks Health care ALLO
NASDAQ · Health careAllogene Therapeutics, Inc. (ALLO)
It posted a net loss of $174.5M. In fiscal 2025 capital spending exceeded operating cash flow by $149.6M. At September 30, 2026 it held $29.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 6, 2026.
Key facts about Allogene Therapeutics, Inc.
- Net worth
- Allogene Therapeutics, Inc. has a market value (market cap) of $322M at the latest share price, and shareholders' equity of $392.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $0 (-100.0% year on year), with a net loss of $190.9M.
- Cash flow
- In fiscal 2025 operations used $149.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 6, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Allogene Therapeutics, Inc.'s next report is expected around March 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Allogene Therapeutics, Inc. does
Allogene Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker ALLO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$190.9M | -$0.87 | -$149.6M |
| 2024 | $22K | -$257.6M | -$1.32 | -$201M |
| 2023 | $95K | -$327.3M | -$2.09 | -$239.2M |
| 2022 | $156K | -$340.4M | -$2.38 | -$225.7M |
| 2021 | $114.1M | -$182.1M | -$1.34 | -$206.3M |
| 2020 | $0 | -$316.4M | -$2.63 | -$181.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Allogene Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026
- November 5, 2026
- October 27, 2026Passive stake changed SCHEDULE 13G/A
- September 30, 2026Activist stake changed SCHEDULE 13D/A
- September 2, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026
- August 12, 2026
- August 12, 2026
- August 7, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Allogene Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $111.7K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 21, 2026 | Parker Geoffrey M.CHIEF FINANCIAL OFFICER | Sold | 36,342 | $48.7K |
| August 21, 2026 | Douglas Earl MartinSVP, General Counsel | Sold | 29,697 | $63K |
| June 18, 2026 | Kazam Joshua ADirector | Exercised options | 47,700 | - |
| April 21, 2026 | Yoshiyama AnnieSVP, Finance | Sold | 9,586 | $22.1K |
| March 31, 2026 | Beneski Benjamin MachinasSVP, Chief Technical Officer | Sold | 2,867 | $7.2K |
| March 16, 2026 | Chang David DPresident and CEO, Director | Sold | 47,763 | $118K |
| March 16, 2026 | Beneski Benjamin MachinasSVP, Chief Technical Officer | Sold | 4,835 | $11.9K |
| March 2, 2026 | Beneski Benjamin MachinasSVP, Chief Technical Officer | Sold | 7,132 | $18.5K |
Who owns ALLO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| BlackRock, Inc.13G, passive | 6.7% | October 27, 2026 |
| Frazier Life Sciences Public Fund, L.P.13G, passive with 13 related filers | 5.6% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 209 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 30,146,963 | +11,055,868 |
| Pfizer Inc | 22,032,040 | 0 |
| Frazier Life Sciences Management, L.P. | 22,446,668 | +18,650,000 |
| State Street Corp | 19,025,826 | +10,365,520 |
| Tpg GP A, LLC | 18,716,306 | 0 |
| Sio Capital Management, LLC | 13,323,431 | new |
| Primecap Management Co | 13,123,440 | +4,743,600 |
| Vanguard Capital Management LLC | 12,166,636 | +5,245,286 |
| Fmr LLC | 12,009,043 | +10,419,213 |
| Citadel Advisors LLC | 10,087,770 | +3,294,150 |
| Two Sigma Investments, LP | 7,784,348 | +2,408,892 |
| Geode Capital Management, LLC | 7,049,328 | +2,925,150 |
| Goldman Sachs Group Inc | 6,148,959 | +3,382,715 |
| GordonMD Global Investments LP | 5,298,000 | +3,868,000 |
| Marshall Wace, Llp | 5,095,408 | +1,647,424 |
| Patient Square Capital LP | 5,050,000 | +1,600,000 |
| Aberdeen Group plc | 5,001,752 | +3,539,533 |
| Millennium Management LLC | 4,843,889 | +1,521,836 |
| D. E. Shaw & Co., Inc. | 4,710,735 | +1,946,959 |
| Morgan Stanley | 4,509,962 | +3,511,117 |
Insiders
7 insiders reported holding 7,984,227 shares in total, about $7.4M at the last price.
| Holder | Shares |
|---|---|
| Chang David DPresident and CEO, Director | 5,150,599 |
| Parker Geoffrey M.CHIEF FINANCIAL OFFICER | 1,045,877 |
| Roberts ZacharyEVP of R&D | 581,166 |
| Douglas Earl MartinSVP, General Counsel | 488,267 |
| Kazam Joshua ADirector | 398,463 |
| Beneski Benjamin MachinasSVP, Chief Technical Officer | 195,338 |
| Yoshiyama AnnieSVP, Finance | 124,517 |
Questions about ALLO
What does Allogene Therapeutics, Inc. do?
Allogene Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as ALLO. Its shares trade on NASDAQ under the ticker ALLO.
What is Allogene Therapeutics, Inc.'s net worth?
Allogene Therapeutics, Inc. has a market value (market cap) of $322M at the latest share price, and shareholders' equity of $392.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Allogene Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $174.5M.
When did Allogene Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 6, 2026. It covers the period to September 30, 2026.
When is Allogene Therapeutics, Inc.'s next earnings report?
Allogene Therapeutics, Inc.'s next report is expected around March 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ALLO with
Follow ALLO
Get an email when Allogene Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Allogene Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.